BL22 immunotoxin (CAT-3888)
No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
- Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. link to original article PubMed
- Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article link to PMC article PubMed
Also known as
- Code names: CAT-3888, GCR-3888